January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly ...
The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...
New options for testing and treating some of the most common sexually transmitted diseases are becoming available.
Researchers with UNC School of Medicine, Gillings School of Global Health, and Lineberger Comprehensive Cancer Center ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Colleen Hagerty Colleen Hagerty is a writer focused on emergency preparedness.
Central to the exhibit will be a live demonstration of the Optikos LensCheckTM featuring Cobot Loading and OpTest® ...
Type V and VI CRISPR/Cas systems have emerged as promising cutting-edge diagnostic tools for nucleic acid detection. Nevertheless, the challenge of low target concentrations necessitates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback